摘要
The truth will set you free but first it will make you miserable.President James A.Garfield There is considerable recent progress in using immune therapy to treat diverse cancers.In hematology this progress is concentrated in therapy of lymphoid cancers including acute lymphoblastic leukemia(ALL),lymphomas,and plasma cell myeloma.Effective therapies include monoclonal antibodies such as rituximab,antibody-drug conjugates such as brentuximab vedotin,antibody-radionuclide conjugates such as 131-iodine tositumomab,bi-specific monoclonal antibodies(BiTE®antibodies)such as blinatumomab and chimeric antigen receptor T-cells(CAR-T-cells)to CD19,CD20,and to BCMA.The target of these immune therapies is B-cell lineage antigens such as CD19,CD20,and BCMA rather than cancer-specific antigens.Efficacy of these interventions is more effective than checkpoint-inhibition directed antibodies such as those to PD-1,or PD-1L or antibodies to CTLA-4 which are more effective in solid cancers.
